Please login to the form below

Not currently logged in


This page shows the latest gout news and features for those working in and with pharma, biotech and healthcare.

Novartis bolsters anti-inflammatory R&D with $1.6bn IFM Tre buy

Novartis bolsters anti-inflammatory R&D with $1.6bn IFM Tre buy

Heading the pack is IFM-2427, an NLRP3 antagonist that has just started a phase 1 clinical trial in healthy volunteers and has potential in chronic inflammatory disorders, including gout, atherosclerosis

Latest news

More from news
Approximately 9 fully matching, plus 38 partially matching documents found.

Latest Intelligence

  • Grünenthal's relentless pursuit of relief Grünenthal's relentless pursuit of relief

    We are involved in projects that go beyond pain - backed by our licence agreement with AstraZeneca for Zurampic in gout, a condition that causes joint pain flares and is diagnosed both

  • Deal Watch January 2017 Deal Watch January 2017

    230. Cymabay. Kowa. Exclusive licence in the US. Arhalofenate for gout p3 ready.

  • Deal Watch October 2016 Deal Watch October 2016

    Gout 2016. Ironwood. Lesinurad US. $265m royalties. Rhinitis 2016. Janssen. Rhinocort outside US.

  • Deal Watch June 2016 Deal Watch June 2016

    Zurampic, a Selective Uric Acid Reabsorption Inhibitor (SURI), works selectively to complement xanthine oxidase inhibitors (XOIs) in the treatment of hyperuricaemia associated with uncontrolled gout, and was approved by the EMA ... licence. 270.

  • Deal Watch April 2016 Deal Watch April 2016

    Another deal worth pondering about is the $265m exclusive license by AstraZeneca (AZ) of the approved Zurampic (lesuranid) plus a fixed dose combination with allopurinol for treatment of gout. ... 450. AstraZeneca (UK). Ironwood (US). US license and

More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.

Latest from PMHub


    She also has gout, an inflammatory condition that affects one in 40 adults in the UK and is on the rise. ... Could these low goals for treatment, alongside the hard-to-shift perception of gout, mean that doctors are not motivated to change their behaviour

  • Patient Perspective: Gout

    What is it like to live with gout? In our latest Patient Perspective interview, we talk to Graham Lewington, who has lived with this form of arthritis for over 25 years. ... Listen to a first-hand account of the symptoms of gout, and how Graham manages

More from PMHub
Approximately 2 fully matching, plus 0 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company
3 Monkeys Zeno

3 Monkeys Zeno is an award winning global creative communications consultancy – home to a collective of creative and strategic...

Latest intelligence

Success breeds success
This week we received the exciting news that we have been shortlisted for the Times Business Awards 2019, Tunbridge Wells in the 'Best Business 1-25 Employees' category....
Turning learning into action: The challenge of behaviour change
Investing in our People
As a small, boutique agency we can and do invest heavily in our team, who produce amazing results for our clients....